CSL Ltd (ASX: CSL) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
CSL Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$80.99 billion
P/E Ratio
18.12
Dividend Yield
2.53%
Shares Outstanding
478.91 million
Earnings per share
-5.350
Dividend per share
4.09
Year To Date Return
-1.47%
Earnings Yield
5.52%
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
CSL Ltd (ASX: CSL)
Latest News
Broker Notes
Buy, hold, sell: CSL, BHP, Westpac shares
Healthcare Shares
Could CSL shares really hit $200? Experts reveal their 12-month targets
ASX Share Market News
ASX 200 healthcare shares soar 9% amid notable FY26 reports from CSL, Pro Medicus
Share Gainers
3 ASX 200 stocks, including CSL, leaping 15% to 23% in this week's sliding market
ASX Share Market News
8 ASX shares just upgraded by the experts
Healthcare Shares
Why I'd buy CSL, Cochlear, and Pro Medicus shares
Healthcare Shares
CSL shares are flying higher. Is it too late to buy?
Broker Notes
Buy, hold, sell: BHP, CSL, and HUB24 shares
Healthcare Shares
How much are CSL shares worth? 4 brokers have their say
Blue Chip Shares
3 ASX 200 shares I'd buy for the next decade
Share Gainers
Here are the top 10 ASX 200 shares today
Healthcare Shares
CSL shares: 1 number that investors shouldn't ignore
Frequently Asked Questions
-
CSL was listed on the ASX in June 1994.
-
CSL has paid twice yearly dividends every year since late 1997, a little over three years after the company’s initial listing on the ASX. Up until early 2005, CSL’s dividends were all fully franked. Since then, franking credits have been intermittent.
Since 2021 CSL has paid an unfranked interim dividend in April and a 10% franked final dividend in September/October.
-
CSL has a dividend reinvestment plan, however, it has not been active since 2004. Instead, CSL periodically executes share buybacks as a way of delivering additional returns for shareholders.
-
CSL originally floated in 1994 at $2.30 per share. However, taking into account share buybacks, the adjusted entry price is equivalent to around 76 cents.
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 10 Mar 2026 | $1.8098 | 0.00% | Interim | 09 Apr 2026 |
| 09 Sep 2025 | $2.4508 | 0.00% | Final | 03 Oct 2025 |
| 10 Mar 2025 | $2.0711 | 0.00% | Interim | 09 Apr 2025 |
| 09 Sep 2024 | $2.1746 | 0.00% | Final | 02 Oct 2024 |
| 11 Mar 2024 | $1.7989 | 0.00% | Interim | 03 Apr 2024 |
| 11 Sep 2023 | $2.0078 | 6.42% | Final | 04 Oct 2023 |
| 09 Mar 2023 | $1.6215 | 0.00% | Interim | 05 Apr 2023 |
| 06 Sep 2022 | $1.7583 | 10.00% | Final | 05 Oct 2022 |
| 07 Mar 2022 | $1.4229 | 0.00% | Interim | 06 Apr 2022 |
| 02 Sep 2021 | $1.5897 | 10.00% | Final | 30 Sep 2021 |
| 04 Mar 2021 | $1.3491 | 0.00% | Interim | 01 Apr 2021 |
| 10 Sep 2020 | $1.4696 | 0.00% | Final | 09 Oct 2020 |
| 11 Mar 2020 | $1.4713 | 0.00% | Interim | 09 Apr 2020 |
| 10 Sep 2019 | $1.4545 | 0.00% | Final | 11 Oct 2019 |
| 13 Mar 2019 | $1.2032 | 0.00% | Interim | 12 Apr 2019 |
| 11 Sep 2018 | $1.2782 | 0.00% | Final | 12 Oct 2018 |
| 14 Mar 2018 | $1.0050 | 0.00% | Interim | 13 Apr 2018 |
| 12 Sep 2017 | $0.0000 | 0.00% | Final | 13 Oct 2017 |
| 15 Mar 2017 | $0.8378 | 0.00% | Interim | 13 Apr 2017 |
| 13 Sep 2016 | $0.8867 | 0.00% | Final | 07 Oct 2016 |
| 23 Mar 2016 | $0.8147 | 0.00% | Interim | 15 Apr 2016 |
| 07 Sep 2015 | $0.8999 | 0.00% | Final | 02 Oct 2015 |
| 16 Mar 2015 | $0.7439 | 0.00% | Interim | 10 Apr 2015 |
| 08 Sep 2014 | $0.6485 | 0.00% | Final | 03 Oct 2014 |
| 05 Mar 2014 | $0.5888 | 0.00% | Interim | 04 Apr 2014 |
| 09 Sep 2013 | $0.5698 | 0.00% | Final | 04 Oct 2013 |
| 05 Mar 2013 | $0.3406 | 0.00% | Interim | 05 Apr 2013 |
| 17 Sep 2012 | $0.3290 | 0.00% | Final | 12 Oct 2012 |
| 14 Mar 2012 | $0.2520 | 0.00% | Interim | 13 Apr 2012 |
| 19 Sep 2011 | $0.3210 | 6.23% | Final | 14 Oct 2011 |
| 08 Mar 2011 | $0.2450 | 0.00% | Interim | 08 Apr 2011 |
| 13 Sep 2010 | $0.3308 | 15.96% | Final | 08 Oct 2010 |
| 09 Mar 2010 | $0.2450 | 0.00% | Interim | 09 Apr 2010 |
| 14 Sep 2009 | $0.2800 | 0.00% | Final | 09 Oct 2009 |
| 17 Sep 2007 | $0.4675 | 58.82% | Final | 12 Oct 2007 |
| 14 Mar 2006 | $0.1960 | 0.00% | Interim | 13 Apr 2006 |
| 30 Aug 2005 | $0.0753 | 23.64% | Special | 10 Oct 2005 |
| 30 Aug 2005 | $0.3000 | 100.00% | Final | 10 Oct 2005 |
| 29 Mar 2004 | $0.1200 | 100.00% | Interim | 13 Apr 2004 |
CSL ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About CSL Ltd
CSL Limited (ASX: CSL) is an Australian-based global biotechnology company that develops and delivers biotherapies and vaccines to protect public health and help people with life-threatening medical conditions live full lives.
CSL has been in operation for more than a century and was listed on the ASX in 1994. Today, the blue-chip healthcare company is one of the largest on the ASX.
CSL’s operational businesses include CSL Behring, CSL Seqirus and CSL Vifor. Its Plasma business operates one of the largest plasma collection networks in the world. CSL is recognised for its global leadership in three main areas: rare and serious diseases, vaccine development, and iron deficiency and nephrology (kidney research).
The company operates in over 40 countries, predominantly Australia, the United States, Germany, the United Kingdom, and Switzerland.
CSL Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 21 Aug 2026 | $168.30 | $-2.90 | -1.69% | 2,686,531 | $170.00 | $171.54 | $166.28 |
| 20 Aug 2026 | $171.20 | $4.72 | 2.84% | 3,463,800 | $169.99 | $175.94 | $169.53 |
| 19 Aug 2026 | $166.48 | $8.66 | 5.49% | 3,879,713 | $159.27 | $166.48 | $159.25 |
| 18 Aug 2026 | $157.82 | $23.22 | 17.25% | 3,707,429 | $148.65 | $159.25 | $148.41 |
| 17 Aug 2026 | $134.60 | $-1.90 | -1.39% | 865,737 | $135.50 | $137.20 | $134.60 |
| 14 Aug 2026 | $136.50 | $-1.02 | -0.74% | 1,276,498 | $136.21 | $138.15 | $135.88 |
| 13 Aug 2026 | $137.52 | $-0.92 | -0.66% | 1,179,398 | $138.65 | $138.94 | $136.31 |
| 12 Aug 2026 | $138.44 | $0.11 | 0.08% | 1,043,685 | $137.56 | $138.49 | $136.46 |
| 11 Aug 2026 | $138.33 | $3.86 | 2.87% | 1,152,737 | $134.85 | $139.03 | $134.24 |
| 10 Aug 2026 | $134.47 | $2.28 | 1.72% | 837,360 | $132.00 | $134.47 | $131.85 |
| 07 Aug 2026 | $132.19 | $-0.17 | -0.13% | 779,357 | $131.01 | $132.92 | $130.80 |
| 06 Aug 2026 | $132.36 | $1.70 | 1.30% | 1,125,931 | $131.55 | $133.35 | $130.86 |
| 05 Aug 2026 | $130.66 | $1.83 | 1.42% | 1,118,928 | $128.83 | $130.75 | $128.31 |
| 04 Aug 2026 | $128.83 | $4.53 | 3.64% | 1,133,249 | $125.40 | $128.83 | $125.07 |
| 03 Aug 2026 | $124.30 | $1.24 | 1.01% | 709,405 | $121.99 | $124.83 | $121.87 |
| 31 Jul 2026 | $123.06 | $-4.87 | -3.81% | 1,930,683 | $127.00 | $127.10 | $121.70 |
| 30 Jul 2026 | $127.93 | $-0.14 | -0.11% | 1,425,642 | $128.99 | $128.99 | $125.71 |
| 29 Jul 2026 | $128.07 | $8.55 | 7.15% | 2,836,774 | $123.43 | $128.75 | $123.43 |
| 28 Jul 2026 | $119.52 | $3.13 | 2.69% | 739,358 | $116.50 | $119.52 | $116.02 |
| 27 Jul 2026 | $116.39 | $2.17 | 1.90% | 639,541 | $115.93 | $117.04 | $114.26 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 01 Jun 2026 | Carolyn Hewson | Buy | 1,036 | $99,342 |
On-market trade.
|
| 26 May 2026 | Gordon Naylor | Buy | 1,100 | $107,800 |
On-market trade.
|
| 15 May 2026 | Alison Watkins | Buy | 2,540 | $250,595 |
On-market trade.
|
| 06 Mar 2026 | Gordon Naylor | Issued | 39,579 | $5,789,220 |
Issue of securities. 39,579 Restricted Share Units
|
| 19 Feb 2026 | Cameron Price | Issued | 263 | $40,105 |
Director remuneration. Volume Weighted Average Price of $152.492553 per Right. 263 rights
|
| 19 Feb 2026 | Constantine Saroukos | Issued | 512 | $78,076 |
Director remuneration. Volume Weighted Average Price of $152.492553 per Right. 512 rights
|
| 17 Feb 2026 | Alison Watkins | Exercise | 214 | $32,433 |
Conversion of securities. Nil consideration, 213 Rights
|
| 17 Feb 2026 | Alison Watkins | Buy | 214 | $32,433 |
Conversion of securities. Nil consideration
|
| 17 Feb 2026 | Carolyn Hewson | Exercise | 244 | $36,980 |
Conversion of securities. Nil consideration, 244 Rights
|
| 17 Feb 2026 | Carolyn Hewson | Buy | 244 | $36,980 |
Conversion of securities. Nil consideration
|
| 17 Feb 2026 | Robert Cuthbertson | Exercise | 183 | $27,735 |
Conversion of securities. Nil consideration, 183 Rights
|
| 17 Feb 2026 | Robert Cuthbertson | Buy | 183 | $27,735 |
Conversion of securities. Nil consideration
|
| 17 Feb 2026 | Brian McNamee | Exercise | 433 | $65,625 |
Conversion of securities. Nil consideration, 433 Rights
|
| 17 Feb 2026 | Brian McNamee | Buy | 433 | $65,625 |
Conversion of securities. Nil consideration
|
| 17 Feb 2026 | Samantha (Sam) Lewis | Exercise | 153 | $23,188 |
Conversion of securities. Nil consideration, 152 Rights held
|
| 17 Feb 2026 | Samantha (Sam) Lewis | Buy | 153 | $23,188 |
Conversion of securities. Nil consideration
|
| 18 Nov 2025 | Brian Daniels | Buy | 3,400 | $99,746 |
On-market trade. US$, 1,700 ADRs (representing 3,400 ordinary shares)
in CSL Limited. |
| 29 Oct 2025 | Paul McKenzie | Issued | 58,360 | $9,966,137 |
As advised by the company. 140,520 Performance Share Units
|
| 01 Sep 2025 | Paul McKenzie | Exercise | 8,101 | $1,703,397 |
Conversion of securities. 82,160 Performance Share Units
|
| 01 Sep 2025 | Paul McKenzie | Sell | 3,699 | $772,402 |
On-market trade.
|
| 01 Sep 2025 | Paul McKenzie | Expiry | 13,261 | $2,788,390 |
As advised by the company. Lapsed, 90,261 Rights
|
| 01 Sep 2025 | Paul McKenzie | Issued | 8,101 | $1,703,397 |
Conversion of securities.
|
| 27 Aug 2025 | Elaine Sorg | Issued | 244 | $53,525 |
Director remuneration. Weighted Average Price. 416 Rights
|
| 27 Aug 2025 | Brian Daniels | Issued | 244 | $53,525 |
Director remuneration. Weighted Average Price of $219.368283
364 rights |
| 27 Aug 2025 | Carolyn Hewson | Issued | 488 | $107,051 |
Director remuneration. 488 Rights. Weighted Average Price
|
| 27 Aug 2025 | Megan Clark | Issued | 366 | $80,288 |
Director remuneration. 366 Rights. Weighted Average Price
|
| 27 Aug 2025 | Robert Cuthbertson | Issued | 366 | $80,288 |
Director remuneration. Weighted Average Price. 366 rights
|
| 27 Aug 2025 | Marie McDonald | Issued | 244 | $53,525 |
Director remuneration. Weighted Average Price. 244 rights
|
| 27 Aug 2025 | Samantha (Sam) Lewis | Issued | 305 | $66,907 |
Director remuneration. Weighted Average Price. 305 rights
|
| 27 Aug 2025 | Alison Watkins | Issued | 427 | $93,670 |
Director remuneration. Weighted Average Price 427 rights
|
| 27 Aug 2025 | Brian McNamee | Issued | 866 | $189,972 |
Director remuneration. Weighted Average Price. 866 Rights
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Ms Carolyn Judith Hewson | Non-Executive Director | Dec 2019 |
Ms Hewson is a former investment banker with over 35 years' experience in the finance sector. She was previously an executive director of Schroders Australia Limited and has financial markets, risk management and investment management expertise. She has long-term non-executive experience in a number of sectors bringing a breadth of experience and insight on strategy, capital management and portfolio optimisation through cycles, financial and non-financial risk, social value, organisational culture and the changing external environment. She is the chairperson of the Corporate Governance Committee; and a member of the Risk Management Committee; and Human Resources and Remuneration Committee.
|
| Ms Alison Mary Watkins | Non-Executive Director | Aug 2021 |
Ms Watkins brings experience through the executive and non executive roles she has held across industries, including manufacturing, agriculture, consumer goods, retail and financial services. She is a Member of the Reserve Bank Monetary Policy Board (since March 2025) and 2025). She is Chair of the Risk Management Committee, Member of the Human Resources Committee, Member of the Corporate Governance Committee and a Member of the Disclosure Committee.
|
| Dr Brian Anthony McNamee | Non-Executive DirectorNon-Executive Chairman | Jan 1990 |
Dr McNamee has executive experience in the biopharmaceutical industry, with a focus on strategy. He has served as a senior advisor to private equity group Kohlberg Kravis Roberts. He has also pursued a number of private equity interests in small cap healthcare companies. He is a member of Innovation and Development Committee; Disclosure Committee; and Corporate Governance Committee.
|
| Dr Robert Andrew Cuthbertson | Non-Executive Director | Oct 2018 |
Dr Cuthbertson has over 35 years' experience in medical research and biotech development with large biopharmaceutical companies and medical organisations. He also has non-executive director experience. He spent five years working in molecular biology research as a staff member at the Howard Florey Institute in Melbourne, Australia, and the National Institutes of Health in Maryland, United States. In 2016, he was made an Officer of the Order of Australia and appointed Enterprise Professor at the University of Melbourne. He is the chairperson of the nnovation and Development Committee; and member of the Corporate Governance Committee.
|
| Ms Samantha (Sam) Louise Lewis | Non-Executive Director | Jan 2024 |
Ms Lewis is an experienced non-executive director serving on boards of ASX 100 companies since 2014. She has experience in accounting, finance, auditing, risk management, corporate governance, capital markets and due diligence. She was a partner at Deloitte. In that role, she acted as lead auditor of a number of Australian listed entities and provided accounting and transactional advisory services including due diligence, IPOs and debt/equity raisings. She has experience working with companies in the manufacturing, retail and industrial sectors. She is a member of the Risk Committee.
|
| Mr Gordon Naylor | Chief Executive OfficerManaging Director | Dec 2025 |
Mr Naylor is a seasoned global biotechnology executive with more than three decades of leadership experience across operations, finance, IT and advanced manufacturing. Beginning his career as an engineer. He is a member of the Innovation and Development Committee; and Disclosure Committee.
|
| Ms Elaine Sorg | Non-Executive Director | Sep 2024 |
Ms Sorg has more than 35 years of experience as a senior executive with leading pharmaceutical companies including AbbVie and Eli Lilly. Prior to her retirement in 2023, Ms Sorg was Senior Vice President for AbbVie and President of AbbVie's US commercial operations. Ms Sorg's experience extends across biopharmaceutical industry and brands across therapeutic areas as well as segments. She is a Member of the Innovation and Development Committee and Human Resources Committee.
|
| Dr Brian Daniels | Non-Executive Director | Dec 2024 |
Dr Daniels has over 30 years' experience in clinical development, medical affairs, commercialisation and biotech investing. Dr Daniels is currently a partner at 5AM Ventures, joining as a Venture Partner in 2014 and becoming a Partner in 2018. Dr Daniels spent more than 20 years in clinical drug development, including leading the Development and Medical Affairs division at Bristol-Myers Squibb. He directed the development of numerous innovative medicines across a number of therapeutic areas including in Cardio-Vascular, Virology and Oncology. He is a member of the Innovation and Development Committee.
|
| Mr Cameron Bruce Price | Non-Executive Director | Oct 2025 |
Mr Price has experience in global investment markets, risk management, public affairs, and legal strategy and compliance. Until mid-2025, he was General Counsel and Chief Risk Officer at the Future Fund. He was partner and Board member at law firm Allens for 25 years, specialising in mergers & acquisitions, equity capital markets and corporate governance and compliance. He is the chairperson of the Human Resources Committee and a member of the Corporate Governance Committee.
|
| Mr Constantine Saroukos | Non-Executive Director | Dec 2025 |
Mr Saroukos has over 25 years' experience in the pharmaceutical sector. He was previously the Global Chief Financial Officer and a Board member for Takeda Pharmaceuticals, based in Tokyo. Before joining Takeda, He held senior roles at Allergan Asia Ltd, including Vice President Finance Asia Pacific and Regional CFO for Greater China & Japan. He also spent more than 13 years with Merck & Co. He is a member of the Human Resources Committee; and Innovation and Development Committee.
|
| Ms Fiona Mead | Company SecretaryHead of Group Governance | Jun 2018 |
-
|
| Ken Lim | CFO |
-
|
|
| Mark Hill | Chief Information Officer |
-
|
|
| Fiona Mead | Company SecretaryHead of Group Governance |
-
|
|
| Kate Priestman | Other Corporate Officer |
-
|
|
| Amy Van Buren | Other Corporate Officer |
-
|
|
| Andy Schmeltz | Other Executive Officer |
-
|
|
| Diego Sacristan | Other Executive Officer |
-
|
|
| Herve Gisserot | Vice President Divisional |
-
|
|
| Mary Oates | Vice President Divisional |
-
|
|
| Stephen Marlow | Vice President Divisional |
-
|
|
| Bill Mezzanotte | Vice President Divisional |
-
|
|
| David Ross | Vice President Divisional |
-
|
|
| Greg Boss | Vice President Divisional |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 150,087,417 | 31.34% |
| J P Morgan Nominees Australia Pty Limited | 70,299,585 | 14.68% |
| Citicorp Nominees Pty Limited | 58,720,703 | 12.26% |
| BNP Paribas Noms Pty Ltd | 14,826,518 | 3.10% |
| BNP Paribas Nominees Pty Ltd <Agency Lending A/C> | 10,909,595 | 2.28% |
| BNP Paribas Nominees Pty Ltd <Deutsche Bank TCA> | 5,358,604 | 1.12% |
| BNP Paribas Nominees Pty Ltd <Hub24 Cusotdial Serv Ltd> | 4,306,104 | 0.90% |
| HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> | 3,552,043 | 0.74% |
| Netwealth Investments Limited <Wrap Services A/C> | 3,337,178 | 0.70% |
| Australian Foundation Investment Company Limited | 2,318,500 | 0.48% |
| Solium Nominees (Australia) Pty Ltd <Allocated A/C> | 1,961,661 | 0.41% |
| Argo Investments Limited | 1,555,309 | 0.32% |
| BNP Paribas Noms (NZ) Ltd | 1,546,456 | 0.32% |
| Citicorp Nominees Pty Limited <Colonial First State Inv A/C> | 1,437,883 | 0.30% |
| Mutual Trust Pty Ltd | 1,413,845 | 0.30% |
| Solium Nominees (Australia) Pty Ltd <VSA A/C> | 1,267,605 | 0.26% |
| Ubs Nominees Pty Ltd | 1,008,541 | 0.21% |
| BNP Paribas Nominees Pty Ltd <IB AU Noms Retailclient> | 872,210 | 0.18% |
| Netwealth Investments Limited <Super Services A/C> | 843,700 | 0.18% |
| D W S Nominees Pty Ltd | 793,208 | 0.17% |
